Nature Communications (Apr 2018)
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
- Huiping Li,
- Jiang Liu,
- Jianing Chen,
- Huiyun Wang,
- Linbin Yang,
- Fei Chen,
- Siting Fan,
- Jing Wang,
- Bin Shao,
- Dong Yin,
- Musheng Zeng,
- Mengfeng Li,
- Jun Li,
- Fengxi Su,
- Qiang Liu,
- Herui Yao,
- Shicheng Su,
- Erwei Song
Affiliations
- Huiping Li
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute
- Jiang Liu
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Jianing Chen
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Huiyun Wang
- State Key Laboratory of Oncology in Southern China, Tumor Center, Sun Yat-sen University
- Linbin Yang
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Fei Chen
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Siting Fan
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Jing Wang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute
- Bin Shao
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute
- Dong Yin
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Musheng Zeng
- State Key Laboratory of Oncology in Southern China, Tumor Center, Sun Yat-sen University
- Mengfeng Li
- Zhongshan School of Medicine, Sun Yat-sen University
- Jun Li
- Zhongshan School of Medicine, Sun Yat-sen University
- Fengxi Su
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Qiang Liu
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Herui Yao
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Shicheng Su
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Erwei Song
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- DOI
- https://doi.org/10.1038/s41467-018-03537-w
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 13
Abstract
Resistance to therapy is a significant issue for patients with metastatic breast cancer (MBC). Here the authors analyze total miRNA from serum samples of 386 MBC patients before treatment with a follow up of 31 months and define a four miRNA signature that predicts the therapeutic benefit of trastuzumab.
